Maynard Um
-
-
-
-
-
-
-
Kymera Therapeutics (KYMR) Tops Q1 EPS by 17c
-
-
-
-
-
-
-
Kymera Therapeutics (KYMR) PT Lowered to $123 at Morgan Stanley
-
-
-
-
-
-
-
Kymera Therapeutics outlines 2026 clinical trial plans
-
-
-
-
-
-
-
Kymera Therapeutics (KYMR) PT Raised at Piper Sandler Following Positive BroADen Data
-
-
-
-
-
-
-
Kymera Therapeutics (KYMR) Halted, News Pending
-
-
-
-
-
-
-
Kymera Therapeutics (KYMR) Misses Q3 EPS by 18c
-
-
-
-
-
-
-
Kymera Therapeutics (KYMR) PT Raised to $68 at Truist Securities
-
402,462 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

